Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report-Reference-Cited by-同舟云学术

Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report

Published:2022-12-02 Issue:48 Volume:101 Page:e32076
ISSN:1536-5964
Container-title:Medicine
language:en
Short-container-title:

Author:

Wen Yan-Ping,Xiao Hai-Wei,Yin Ju-Hua,Guo Hui-Ru,Shan Meng-Jun,Shen Li-Ping,Liu Ling-Shuang

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference33 articles.

1. A review of cancer immunotherapy toxicity;Kennedy;CA Cancer J Clin,2020

3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016

5. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncommon Adverse Events of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Case Reports;Cancers;2024-05-16

2. Atezolizumab-Induced Type 1 Diabetic Ketoacidosis in a Patient With Small Cell Lung Cancer and Pre-existing Type 2 Diabetes Mellitus;Cureus;2024-03-27

3. Urinary Retention Following Methamphetamine and Cannabis Abuse in a 33-Year-Old Male;Cureus;2024-03-27

4. Persistent nivolumab-induced urticaria with vibratory and delayed-pressure angioedema;The Journal of Allergy and Clinical Immunology: In Practice;2024-01

5. Durvalumab;Reactions Weekly;2023-01-07